ReviewCureus2026
Suzetrigine: A Selective Inhibitor of the NaV1.8 Sodium Channel.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid related adverse events are an important perioperative concern despite widespread adoption of combined analgesic approaches for pain management. Suzetrigine, a selective inhibitor of the NaV1.8 sodium channel for the treatment of moderate-to-severe acute pain, enables the use of a novel analgesic class in clinical practice. The goal of this scoping review is to analyze suzetrigine's pharmacokinetic, pharmacodynamic, and clinical evidence. Utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines, the online databases of PubMed, Embase, and ClinicalTrials.gov (January 2020 to February 2026) were systematically searched for various studies investigating NaV1.8-selective compounds in acute pain contexts. A total of five reviewers screened and extracted data with cross-examination. A total of 10 articles were identified to meet the specified inclusion criteria for this scoping review. These articles were recognized as peer-reviewed publications, clinical trial registry results, regulatory documents, conference abstracts, and preprints. Suzetrigine was found to be most effective when given orally twice daily, and its selectivity for NaV1.8 was up to 30,000 times greater than that of other sodium channel medications pursuing the same effect. Suzetrigine was associated with a decrease in gastrointestinal symptoms when compared to opioid counterparts, a decrease of up to 40%. Mechanistic studies reveal that NaV1.8 inhibition reduces, but does not abolish, pain receptor firing, explaining the meaningful yet incomplete analgesia observed clinically. Suzetrigine is also metabolized by cytochrome P4503A (CYP3A) enzymes, suggesting potential drug interactions. Suzetrigine provides a unique mechanism to relieve acute pain without opioids. Current evidence gaps include limited data across comprehensive surgical populations, multimodal comparative effectiveness of trials, and undefined safety outcomes. Perioperative analgesic regimens can be optimized by prioritizing research addressing areas with insufficient evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.